Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.

Since there is no cure, disease surveillance and treatment have to be continued long term. Polycythemia vera is a medical ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other ...

Hence, just like low haemoglobin levels (less than 13.2 g/dL for men and 11.6 g/dL for women) necessitate medical ...

Polycythemia vera is a slow growing blood cancer that happens in your bone marrow, the spongy tissue inside bones. It's usually caused by a gene mutation. Your bone marrow makes red blood cells ...

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms; their molecular basis has been appreciated only recently and is briefly discussed in this ...

Protagonist Therapeutics has 2 attractive late-stage pipeline assets, but commercialized sales will not begin until 2027.

Hi. I'm Ron. I'm a polycythemia patient, and I've had the disease for over 25 years. I was originally diagnosed at the age of 38. And I'm here to talk to you about symptom management and talking ...

The prevalence JAK2 V617F proteins in the general population is about 0.2%. In people with polycythemia vera (PV), JAK2 V617F mutations are present in 96% of cases. JAK2 mutations lead to health ...

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of ...

Testosterone. Even the word alone sounds manly. For men, testosterone is important for drive, fertility, heart health, bone ...